The camptothecins: unfolding their anticancer potential
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
New York, NY
New York Acad. of Sciences
2000
|
| Schriftenreihe: | New York Academy of Sciences: Annals of the New York Academy of Sciences
922 |
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XII, 363 S. Ill., graph. Darst. |
| ISBN: | 1573312916 1573312924 |
Internformat
MARC
| LEADER | 00000nam a2200000 cb4500 | ||
|---|---|---|---|
| 001 | BV013624842 | ||
| 003 | DE-604 | ||
| 005 | 20010308 | ||
| 007 | t | ||
| 008 | 010308s2000 ad|| |||| 10||| eng d | ||
| 020 | |a 1573312916 |9 1-57331-291-6 | ||
| 020 | |a 1573312924 |9 1-57331-292-4 | ||
| 035 | |a (OCoLC)610878056 | ||
| 035 | |a (DE-599)BVBBV013624842 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-20 |a DE-12 | ||
| 245 | 1 | 0 | |a The camptothecins |b unfolding their anticancer potential |c ed. by Joachim G. Liehr ... |
| 264 | 1 | |a New York, NY |b New York Acad. of Sciences |c 2000 | |
| 300 | |a XII, 363 S. |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 490 | 1 | |a New York Academy of Sciences: Annals of the New York Academy of Sciences |v 922 | |
| 650 | 0 | 7 | |a Camptothecin |0 (DE-588)4147230-5 |2 gnd |9 rswk-swf |
| 650 | 0 | 7 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |2 gnd |9 rswk-swf |
| 655 | 7 | |0 (DE-588)1071861417 |a Konferenzschrift |y 2000 |z Arlington Va. |2 gnd-content | |
| 689 | 0 | 0 | |a Camptothecin |0 (DE-588)4147230-5 |D s |
| 689 | 0 | |5 DE-604 | |
| 689 | 1 | 0 | |a Krebs |g Medizin |0 (DE-588)4073781-0 |D s |
| 689 | 1 | 1 | |a Camptothecin |0 (DE-588)4147230-5 |D s |
| 689 | 1 | |5 DE-604 | |
| 700 | 1 | |a Liehr, Joachim G. |e Sonstige |4 oth | |
| 830 | 0 | |a New York Academy of Sciences: Annals of the New York Academy of Sciences |v 922 |w (DE-604)BV002532608 |9 922 | |
| 856 | 4 | 2 | |m Digitalisierung TU Muenchen |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009307481&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-009307481 | ||
Datensatz im Suchindex
| _version_ | 1804128432025501696 |
|---|---|
| adam_text | ANNALS OF THE NEW YORK ACADEMY OF SCIENCES
Volume
922
December
2000
THE CAMPTOTHECINS
UNFOLDING THEIR
ANTICANCER
POTENTIAL
Editors and Conference Organizers
Joachim G. Liehr, Beppino
С
Giovanella, and
Claire F. Verschraegen
[Ibis volume is the result of a conference entitled The Camptothecins: Unfolding Their
Anticancer
Potential held by the New York Academy of Sciences and Pharmacia
&
Up¬
john on March
17-20, 2000
in Arlington, Virginia.]
CONTENTS
Introduction. By Joachim G. Liehr and Beppino Giovanella
..........
xi
Keynote Lecture
Mechanism of Action of Camptothecin. By
Leroy F.
Liu, Shyamal D.
Desai, Tsai-Kun Li, Yong Mao,
Mei
Sun, and Sai-Peng Sim
.....
l
Part I. Mechanism of Action of Camptothecins
Molecular and Biological Determinants of the Cytotoxic Actions of Campto¬
thecins. Perspective for the Development of New Topoisomerase I
Inhibitors. By Kurt W. Kohn and
Yves Pommier
................ 11
Dependence of
Anticancer
Activity of Camptothecins on Maintaining Their
Lactone Function. By B.C. Giovanella,
N.
Harris, J.
Mendoza,
Z.
Cao,
J. Liehr, and J.S. Stehlin
............................. 27
Camptothecin Design
and Delivery Approaches for Elevating Anti-
Topoisomerase I Activities in Vivo. By THOMAS G. BURKE AND
David Bom
................................................. 36
Mechanisms of Resistance to Camptothecins. By Ahamed Saleem, Troy K.
Edwards, Zeshaan Rasheed, and Eric H. Rubin
............... 46
Part II. Mechanism-Based Design and Synthesis
of Novel Camptothecins
Structure-Based Analysis of the Effects of Camptothecin on the Activities of
Human Topoisomerase I. By James J. Champoux
.................. 56
Mechanisms of
DNA Topoisomerase I-Induced
Cell Killing in the Yeast
Saccharomyces cerevisiae. By
PAOLA FlORANl
AND
Mary-Ann Bjornsti
......................................... 65
Camptothecins as Probes of the
Microenvironments
of Topoisomerase I
—
DNA
Complexes. By SIDNEY M.
HECHT.......................... 76
Part III. Novel Topoisomerase I Inhibitors
Preclinical and Clinical Trials of Topoisomerase Inhibitors. By
Nagahiro Saijo
............................................. 92
Homocamptothecins:
Е
-Ring
Modified CPT Analogues. By Olivier
Lavergne,
Daniele Demarquay, Philip G.
Kasprzyk, and
Dennis C.H. Bigg
........................................... 100
The Cascade Radical
Annulation
Approach to New Analogues of Campto¬
thecins. Combinatorial Synthesis of Silatecans and Homosilatecans. By
Dennis P.
Curran,
Hubert Josien, David Bom, Ana E.
Gabarda,
and Wu
Du
................................................. 112
Part IV. New Camptothecin Derivatives and Formulations
Structure-Activity Relationship of
Alkyl
Camptothecin Esters. By Zhisong
Cao, Panayotis
Pantazis, John
Mendoza,
Janet Early,
Anthony
Kozielski,
Nick Harris, Dana Vardeman, Joachim
Liehr, John S. Stehlin, and Beppino Giovanella
.............. 122
Conjugation of Camptothecins to Poly-CL-Glutamic Acid). By Jack W. Singer,
Peter
de Vries,
Rama Bhatt, John Tulinsky, Peter Klein,
Chun
Li, Luka Milas,
Robert A. Lewis, and Sidney Wallace
... 136
9-Nitrocamptothecin
Liposome
Aerosol Treatment of Human Cancer Sub¬
cutaneous Xenografts and Pulmonary Cancer
Métastases
in Mice. By
Vernon Knight, Eugenie S.
Kleinerman,
J.
Clifford Waldrep,
Beppino
С
Giovanella, Brian E. Gilbert, and
Nadezhda V. Koshkina
...................................... 151
Modified Lactone/Carboxylate Salt Equilibria in Vivo by Liposomal Delivery
of
Ç-Nitro-Camptothecin.
By Diana
S-L.
Chow, Ling Gong,
Michael D. Wolfe, and Beppino
С
Giovanella
............... 164
New Analogues of Camptothecins. Activity and Resistance. By
Epie
Boven,
Annemarie
H. Van
Hattum, Ilse Hoogsteen,
Hennie
M.M.
SCHLÜPER, AND H.M.
PINEDO
.................................. 175
Intraperitoneal Topoisomerase-I
Inhibitors. Preliminary Findings with
9-
Aminocamptothecin. By Franco MuGGiA, Leonard
Liebes,
Milan
Potměšil,
Anne Hamilton, Howard
Höchster,
Gila
Hornreich, Joan Sorich, Andrea Downey, and
Heather
Wasserstrom...................................... 178
PartV. Pharmacology
Transport of Topoisomerase I Inhibitors by the Breast Cancer Resistance
Protein. Potential Clinical Implications. By
Jan H.M. Schellens,
Marc
Maliepaard, Rik
J.
Scheper,
George
L.
Scheffer,
Johan
W.
Jonker,
Johan
W.
Smit,
Jos
H.
Beunen,
and
Alfred H.
Schinkel
......................................... 188
Pharmacokinetics
of Orally Administered Camptothecins. By Elora Gupta,
Viral Vyas, Farheena Ahmed, PatrickSinko, Thomas Cook, and
Eric Rubin
.................................................. 195
Metabolism of CPT-
11.
Impact on Activity. By LAURENT P. RivoR
Y
....... 205
Pharmacology of Camptothecin Esters. By Joachim G. Liehr,
Nick J. Harris, John
Mendoza,
Ahmed E. Ahmed, and
Beppino C. Giovanella
...................................... 216
Part VI. Clinical Trials I, Newer Analogues
The Clinical Development of 9-Aminocamptothecin. By Chris H. Takimoto
and Rebecca Thomas
....................................... 224
Alternative Administration of Camptothecin Analogues. By
CF.
Verschraegen, K. Jaeckle, B. Giovanella, V. Knight, and
B.E. Gilbert
................................................ 237
Topotecan (Hycamptin) and Topotecan-Containing Regimens in the Treat¬
ment of
Hematologie
Malignancies. By
Miloslav Beran
and
Hagop M. Kantarjian
................................... 247
f:
Summary of Phase I Clinical Trials. By R.
De Jager,
P. Cheverton, K. Tamanoi, J. Coyle, M.
Ducharme,
N.
Sakamoto,
M. S
atomi,
M.
Suzuki, and the DX^Slf Investigators
......... 260
Part
VII.
Clinical Trials II, Combination Therapy
Cellular and Molecular Responses to Topoisomerase I Poisons. Exploiting
Synergy for Improved Radiotherapy. By Shigeki Miyamoto, Tony T.
Huang, Shelly Wuerzberger-Davis, William G.
Bornmann,
John J. Pink, Colleen Tagliarino, Timothy J. Kinsella, and
David A. boothman
......................................... 274
In Vitro
Antitumor
Activity of 9-Nitro-Camptothecin as a Single Agent and in
Combination with other
Antitumor
Drugs. By Ralph J. Bernacki,
Paula
Pera,
Peter
Gambacorta,
Yseult
Brun,
and
William R. Greco
........................................... 293
p53 and p21 Are Major Cellular Determinants for
DNA
Topoisomerase I-
Mediated Radiation Sensitization in Mammalian Cells. By Allan Y.
Chen, Paul B. Scruggs, Ling Geng, Mace L. Rothenberg, and
Dennis E.
Hallahan
........................................ 298
Part
Vul.
Poster Papers
The Homocamptothecin, BN
80927,
Is a Potent Topoisomerase I Poison and
Topoisomerase II Catalytic Inhibitor
1.
By
Daniele Demarquay,
Hélène
Coulomb, Marion Huchet, Laurence Lesueur-Ginot,
José Cámara,
Olivier Lavergne, and Dennis Bigg
............ 301
The Dual Topoisomerase Inhibitor, BN
80927,
Is Highly Potent against Cell
Proliferation and Tumor Growth. By Marion Huchet,
Daniele
Demarquay,
Hélène
Coulomb, Philip Kasprzyk, Mark
Carlson, Jeffrey
Lauer,
Olivier Lavergne, and Dennis Bigg
.. 303
Ubiquitin, SUMO-l, and UCRP in Camptothecin Sensitivity and Resistance.
By Shyamal D. Desai, Yong Mao,
Mei
Sun, Ts
ai-
Kun
Li, Jiaxi Wu,
and
Leroy F.
Liu
........................................ 306
A Spectrophotometric Study of the pH-Dependent and
DNA
Binding
Properties of Topotecan. By Steven E. Miller and Daniel S. Pilch
. 309
Kinetics of in Vitro Hydrolysis of Homocamptothecins As Measured by
Fluorescence. By D. Chauvier, I. Chourpa, D.C.H. Bigg, and
M. Manfait
................................................. 314
The Combinatorial Synthesis of Racemic Homosilatecan Libraries via a
Cascade Radical
Annulation.
By Wu
Du, Ana E.
Gabarda, David
Bom, and Dennis P.
Curran
.................................. 317
Combined Radiation and 9-Nitrocamptothecin (Rubitecan) in the Treatment
of Locally Advanced Pancreatic Cancer. By K.R. Kemp, J.G. Liehr,
AND B. GlOVANELLA
.......................................... 320
Preclinical and Phase I Clinical Studies with Ckd-602, a Novel Camptothecin
Derivative. By J.H. Lee, J.M. Lee, K.H.
Lim,
J.K. Kim, S.K.
Ahn,
Y.J.
Bang, and C.I. Hong
........................................ 324
Action of Topoisomerase Targeting Drugs on Non-Hodgkin s Lymphoma and
Leukemia. Correlation of Clinical and Cell Culture Studies. By
J.S. Nair, R. Kancherla, K.
Seiter, F.
Tráganos,
and
Y.-C. Tse-Dinh
.............................................. 326
Improvement of Therapeutic Index of Low-Dose Topotecan Delivered per os.
By
Graziella
Pratesi,
Michelandrea De
Cesare,
and
Franco Zunino
............................................. 330
Camptothecin Dose, Schedule, and Timing of Administration for Clinical
Radiation Sensitization. By Twin A. Rich and Alexander V.
Kirichenko
................................................. 334
Rapid Chromatin Reorganization Induced by Topoisomerase I-Mediated
DNA
Damage. By
Mei
Sun, Pu
Duann,
Chin-Tai
Lin, Hui
Zhang,
and
Leroy F.
Liu
............................................ 340
NF-kB Activation in Topoisomerase I Inhibitor-Induced Apoptotic Cell Death
in Human Non-Small Cell Lung Cancer. By Masahiro
Тавата
and
Ram Ganapathi
............................................. 343
Phase I Study of 9-Nitro-20(S)-Camptothecin in Combination with Cisplatin
for Patients with Advanced Malignancies. By
C.F. Verschraegen,
M. Vincent, J.L. Abbruzzese, D.
Siegler,
J.J. Kavanagh,
E. Loyer,
A.P. Kudelka, and E. Rubin
........................ 345
Phase II Study of Intravenous DX-8951f in Patients with Advanced Ovarian,
Tubai, or
Peritoneal Cancer Refractory to Platinum, Taxane, and
Topotecan. By
CF.
Verschraegen,
С
Levenback,
M. Vincent, J.
Wolf, M.
Bevers, E.
Loyer,
A.P. Kudelka, and J.J. Kavanagh
.. 349
Feasibility, Phase I, and Pharmacological Study of Aerosolized Liposomal
9-
Nitro-20(S)-Camptothecin in Patients with Advanced Malignancies in
the Lungs. By
CF.
Verschraegen, B.E. Gilbert, A.J.
Ни
aringa,
R.
Newman,
N.
Harris, F.J. Leyva, L.
Keus,
К.
Campbell,
T.
Nelson-Taylor, and V. Knight
............................ 352
Inhibition of
DNA
Replication in Camptothecin-Treated Cells Is Regulated by
Protein Kinases. By Xiang-Yang Zhou and Ya Wang
............ 355
Part IX. Concluding Remarks
Concluding Remarks. By CLAIRE VERSCHRAEGEN
...................... 360
Index of Contributors
.............................................. 361
Financial assistance was received from:
Co-sponsor
•
PHARMACIA
&
UPJOHN
Supporters
•
AVENTIS PHARMAS
SA
• BIONUMERIK
PHARMACEUTICALS, INC.
•
DAIICHI PHARMACEUTICAL CORPORATION
•
SMITHKLINE BEECHAM PHARMACEUTICALS
•
SUPERGEN
Contributors
•
BAYER CORPORATION
•
BRISTOL-MYERS SQUIBB COMPANY
•
CELL THERAPEUTICS, INC.
•
INSTITUT
HENRI BEAUFOUR
•
ORTHO BIOTECH
•
XECHEM, INC.
•
YAKULT HONSHA CO., LTD
The New York Academy of Sciences believes it has a responsibility to provide an open
forum for discussion of scientific questions. The positions taken by the participants in
the reported conferences are their own and not necessarily those of the Academy. The
Academy has no intent to influence legislation by providing such forums.
|
| any_adam_object | 1 |
| building | Verbundindex |
| bvnumber | BV013624842 |
| ctrlnum | (OCoLC)610878056 (DE-599)BVBBV013624842 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01699nam a2200397 cb4500</leader><controlfield tag="001">BV013624842</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20010308 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">010308s2000 ad|| |||| 10||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1573312916</subfield><subfield code="9">1-57331-291-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1573312924</subfield><subfield code="9">1-57331-292-4</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)610878056</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV013624842</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield><subfield code="a">DE-12</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">The camptothecins</subfield><subfield code="b">unfolding their anticancer potential</subfield><subfield code="c">ed. by Joachim G. Liehr ...</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York, NY</subfield><subfield code="b">New York Acad. of Sciences</subfield><subfield code="c">2000</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XII, 363 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="1" ind2=" "><subfield code="a">New York Academy of Sciences: Annals of the New York Academy of Sciences</subfield><subfield code="v">922</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Camptothecin</subfield><subfield code="0">(DE-588)4147230-5</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="655" ind1=" " ind2="7"><subfield code="0">(DE-588)1071861417</subfield><subfield code="a">Konferenzschrift</subfield><subfield code="y">2000</subfield><subfield code="z">Arlington Va.</subfield><subfield code="2">gnd-content</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Camptothecin</subfield><subfield code="0">(DE-588)4147230-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Camptothecin</subfield><subfield code="0">(DE-588)4147230-5</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Liehr, Joachim G.</subfield><subfield code="e">Sonstige</subfield><subfield code="4">oth</subfield></datafield><datafield tag="830" ind1=" " ind2="0"><subfield code="a">New York Academy of Sciences: Annals of the New York Academy of Sciences</subfield><subfield code="v">922</subfield><subfield code="w">(DE-604)BV002532608</subfield><subfield code="9">922</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung TU Muenchen</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009307481&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-009307481</subfield></datafield></record></collection> |
| genre | (DE-588)1071861417 Konferenzschrift 2000 Arlington Va. gnd-content |
| genre_facet | Konferenzschrift 2000 Arlington Va. |
| id | DE-604.BV013624842 |
| illustrated | Illustrated |
| indexdate | 2024-07-09T18:49:09Z |
| institution | BVB |
| isbn | 1573312916 1573312924 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-009307481 |
| oclc_num | 610878056 |
| open_access_boolean | |
| owner | DE-20 DE-12 |
| owner_facet | DE-20 DE-12 |
| physical | XII, 363 S. Ill., graph. Darst. |
| publishDate | 2000 |
| publishDateSearch | 2000 |
| publishDateSort | 2000 |
| publisher | New York Acad. of Sciences |
| record_format | marc |
| series | New York Academy of Sciences: Annals of the New York Academy of Sciences |
| series2 | New York Academy of Sciences: Annals of the New York Academy of Sciences |
| spelling | The camptothecins unfolding their anticancer potential ed. by Joachim G. Liehr ... New York, NY New York Acad. of Sciences 2000 XII, 363 S. Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier New York Academy of Sciences: Annals of the New York Academy of Sciences 922 Camptothecin (DE-588)4147230-5 gnd rswk-swf Krebs Medizin (DE-588)4073781-0 gnd rswk-swf (DE-588)1071861417 Konferenzschrift 2000 Arlington Va. gnd-content Camptothecin (DE-588)4147230-5 s DE-604 Krebs Medizin (DE-588)4073781-0 s Liehr, Joachim G. Sonstige oth New York Academy of Sciences: Annals of the New York Academy of Sciences 922 (DE-604)BV002532608 922 Digitalisierung TU Muenchen application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009307481&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | The camptothecins unfolding their anticancer potential New York Academy of Sciences: Annals of the New York Academy of Sciences Camptothecin (DE-588)4147230-5 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| subject_GND | (DE-588)4147230-5 (DE-588)4073781-0 (DE-588)1071861417 |
| title | The camptothecins unfolding their anticancer potential |
| title_auth | The camptothecins unfolding their anticancer potential |
| title_exact_search | The camptothecins unfolding their anticancer potential |
| title_full | The camptothecins unfolding their anticancer potential ed. by Joachim G. Liehr ... |
| title_fullStr | The camptothecins unfolding their anticancer potential ed. by Joachim G. Liehr ... |
| title_full_unstemmed | The camptothecins unfolding their anticancer potential ed. by Joachim G. Liehr ... |
| title_short | The camptothecins |
| title_sort | the camptothecins unfolding their anticancer potential |
| title_sub | unfolding their anticancer potential |
| topic | Camptothecin (DE-588)4147230-5 gnd Krebs Medizin (DE-588)4073781-0 gnd |
| topic_facet | Camptothecin Krebs Medizin Konferenzschrift 2000 Arlington Va. |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=009307481&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV002532608 |
| work_keys_str_mv | AT liehrjoachimg thecamptothecinsunfoldingtheiranticancerpotential |